XPS™ approved in Canada
XVIVO Perfusion has obtained approval for the XPS™ (Xvivo Perfusion System) in Canada. This enables clinical use of the XPS™ in Canada.
Health Canada has approved the XPS™ for clinical use in Canada. With its integrated Hamilton C2 ventilator and MAQUET CardioHelp centrifugal pump, the XPS™ is the most flexible and complete platform on the market for EVLP (Ex Vivo Lung Perfusion), and it gives the transplant team full control over the entire process. The design of the XPS™ means that X-rays and automatic measurements of oxygen and pH can be carried out while EVLP evaluation is ongoing. The XPS™ has a user-friendly graphic interface with touchscreen functionality and data capture of the lung’s values during the entire EVLP procedure. This provides the basis for analysis and evaluation before a final clinical decision.
XVIVO Perfusion’s XPS™ and STEEN Solution™ are the only approved products in the USA for evaluation of marginal lungs before transplantation. The XPS™ and STEEN Solution™ are also CE marked in Europe and approved by the TGA for clinical use in Australia. Leading clinics in the USA and Europe have obtained good clinical results when using XPS™.
“We are delighted that the XPS™ is also now available for clinical lung transplantation in Canada, as this means that the XPS™ has now been approved in all the major markets in the world,” says Magnus Nilsson, CEO of XVIVO Perfusion.
November 26, 2015
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on November 26 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: firstname.lastname@example.org. Website: www.xvivoperfusion.com